McAdam LLC Has $623,000 Position in Pfizer Inc. (NYSE:PFE)

McAdam LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.9% during the third quarter, Holdings Channel.com reports. The firm owned 21,533 shares of the biopharmaceutical company’s stock after acquiring an additional 2,628 shares during the period. McAdam LLC’s holdings in Pfizer were worth $623,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Olistico Wealth LLC bought a new position in shares of Pfizer during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the 2nd quarter worth about $29,000. Quarry LP bought a new position in shares of Pfizer during the 2nd quarter worth about $31,000. Trivant Custom Portfolio Group LLC boosted its position in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. bought a new position in shares of Pfizer during the 2nd quarter worth about $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $28.65 on Friday. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The stock’s 50 day moving average price is $29.07 and its 200-day moving average price is $28.48. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.86%. Pfizer’s dividend payout ratio (DPR) is presently -365.21%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on PFE shares. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Wells Fargo & Company raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday. UBS Group raised their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.